Video

Dr. Concepcion on Barriers to Genetic Testing in Community Urology Practices

Raoul S. Concepcion, MD, FACS, discusses barriers to genetic testing for patients with prostate cancer as identified by community urologists.

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses barriers to genetic testing for patients with prostate cancer as identified by community urologists.

Of the 52 urology practices that participated in an 8-question online survey, 32 are currently offering genetic testing to patients who qualify; however, there are several challenges that providers encounter in clinic.

The number 1 challenge identified by 22% of practices concerns medical or legal liability for results that go unaddressed, explains Concepcion.

Secondly, 20% of practices were apprehensive about patient expenses and reimbursement. This is perhaps a reflection of tissue-based somatic testing expenses, says Concepcion.

Finally, the third most commonly cited concern identified by 18% of practices relates to the difficulty of obtaining a complete family history. Historically, urologists have not had to acquire this information; however, it is vital for genetic testing, concludes Concepcion.

Related Videos
Leo I. Gordon, MD
Janaki Neela Sharma, MD, University of Miami
Richard Kim, MD, Moffitt Cancer Center
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.